BRIEF-Mylan invalidates two of Teva's Copaxone patents By: Reuters: Company News August 24, 2016 at 17:09 PM EDT * Mylan invalidates two of Teva's Copaxone 40 mg/ml patents via U.S. Patent and Trademark Office's Inter Partes Review proceeding Read More >> Related Stocks: Mylan Teva Pharmaceutical Industries ADR